Abstract:For many patients, a pancreatic cancer diagnosis involves a dismal (<6%) chance of survival beyond 5 years, and little progress has been made in terms of prevention and early detection of this disease. As a result, most patients present with advanced disease and a poor performance status that often precludes them from receiving aggressive therapy or surgery. Advances in imaging technology, such as multidetector CT, high-field MRI, and PET, have improved staging for patients with pancreatic cancer. In addition, multiagent chemotherapy regimens such as FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin) and gemcitabine with nab-paclitaxel have resulted in significant improvements in survival when compared to gemcitabine monotherapy. Nonetheless, these multiagent regimens can cause more toxicity than single-agent chemotherapy, including nausea, vomiting, infection, and severe neuropathy. These toxicities can be debilitating, particularly with chronic administration. Efforts to include targeted therapies have not been very effective and, unfortunately, often increase rates of treatment-related toxicity. Radiation therapy has been shown to improve local control, stability of disease progression, and pain control in many stages of pancreatic cancer. However, these clinical benefits have historically been limited by (1) the relatively long courses of therapy, which often exceed 5 to 6 weeks; (2) the associated toxicity resulting from a lack of dose conformality; and (3) the fact that concurrent chemoradiation often decreases the ability to give patients full-dose systemic therapy. Recently, however, advances in radiation therapy techniques, including image guidance, target delineation (ie, fiducial markers, dose constraints), and motion management (ie, active breathing control, respiratory gating, respiratory tracking) now allow for very precise irradiation of pancreatic tumors, with an accuracy of 1 mm. This form of therapy, otherwise known as stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR), has now been used in several malignancies, including those of the lung, liver, brain, spine, and prostate. However, its integration into the treatment paradigm of pancreatic cancer has been limited thus far. This slow integration primarily stems from the requirement for increased physical support and findings of several early studies in which SBRT resulted in increased rates of late gastrointestinal toxicity (ie, ulcers, gastrointestinal bleeding). 1–3 More recently, however, single-institution studies and a multi-institution prospective study with SBRT 4–7 have shown acceptable levels of late toxicity with minimal acute toxicity when treatment is delivered over 3 to 5 days as opposed to 1 day. Additionally, SBRT is typically delivered without the need for concurrent chemotherapy, resulting in improved quality of life, less delay in the administration of full-dose systemic therapy, and enhanced integration with other cancer treatment modalities. To date, more than 600 patients with pancreatic cancer have been treated with SBRT, and reports suggest an improvement in pain scores and quality of life. Furthermore, the efficacy and toxicity data compare favorably with those on conventional chemoradiotherapy. Nonetheless, evaluation of SBRT in a prospective randomized trial is necessary to define its role in the management of pancreatic cancer and to ensure its safe implementation for treating patients. Precise delivery of SBRT is particularly important because errors involving any dimension of the planning and treatment process (ie, contouring, target delineation, breathing motion) can significantly increase the risk of toxicity due to the close proximity of adjacent radiosensitive organs (ie, bowel and stomach).

Prospective study on stereotactic body radiotherapy for small pancreatic neuroendocrine tumors: tolerance and effectiveness analysis

Advances Of Stereotactic Body Radiotherapy In Pancreatic Cancer

Neoadjuvant Stereotactic Body Radiotherapy after Upfront Chemotherapy Improves Pathologic Outcomes Compared with Chemotherapy Alone for Patients with Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity

Clinical Effects of Stereotactic Body Radiation Therapy Targeting the Primary Tumor of Liver-Only Oligometastatic Pancreatic Cancer

Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer – A phase II study

Sharing Mono-Institutional Experience of Treating Pancreatic Cancer with Stereotactic Body Radiation Therapy (SBRT)

Stereotactic body radiotherapy compared to conventionally fractionated radiotherapy for locally advanced or oligometastatic pancreatic cancer.

SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases

Influence of Stereotactic Body Radiation Therapy on the Survival of Patients with Early Stage Pancreatic Cancer

Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

Stereotactic body radiation therapy: a new standard option for pancreatic cancer?

Incorporating stereotactic body radiation therapy for inoperable pancreatic cancer.

Neoadjuvant SBRT plus regional nodal irradiation with concurrent capecitabine for patients with resectable pancreatic cancer: Survival analysis of prospective phase 1 trial.

Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database

P3.16-19 Clinical Outcomes of Stereotactic Body Radiation Therapy for T2N0M0 Non-Small Cell Lung Cancer

Analysis of the Efficacy, Safety and Survival Factors of Stereotactic Body Radiation Therapy in Patients with Recurrence of Pancreatic Cancer

A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)

Clinical Outcomes of Stereotactic Body Radiotherapy for De Novo Pulmonary Tumors in Patients with Completely Resected Early Stage Non-Small Cell Lung Cancer

Stereotactic radiotherapy plus anti PD-1 therapy in patients with locally advanced unresectable pancreatic cancer: Results from a phase 1/2 clinical trial (CA209-9KH).

Stereotactic body radiation therapy boost in locally advanced pancreatic cancer

Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study